Morgan Stanley’s Dianthus Therapeutics DNTH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $8.18M | Sell |
97,455
-130,561
| -57% | -$7.56M | ﹤0.01% | 3741 |
|
|
2025
Q4 | $9.4M | Buy |
228,016
+150,496
| +194% | +$5.83M | ﹤0.01% | 3668 |
|
|
2025
Q3 | $3.05M | Sell |
77,520
-60,329
| -44% | -$1.54M | ﹤0.01% | 4517 |
|
|
2025
Q2 | $2.57M | Buy |
137,849
+58,681
| +74% | +$1.1M | ﹤0.01% | 4551 |
|
|
2025
Q1 | $1.44M | Sell |
79,168
-36,881
| -32% | -$813K | ﹤0.01% | 4807 |
|
|
2024
Q4 | $2.53M | Buy |
116,049
+48,764
| +72% | +$1.25M | ﹤0.01% | 4543 |
|
|
2024
Q3 | $1.84M | Buy |
67,285
+40,324
| +150% | +$1.12M | ﹤0.01% | 4709 |
|
|
2024
Q2 | $698K | Buy |
26,961
+5,877
| +28% | +$141K | ﹤0.01% | 5146 |
|
|
2024
Q1 | $633K | Buy |
21,084
+20,974
| +19,067% | +$456K | ﹤0.01% | 5203 |
|
|
2023
Q4 | $1.14K | Sell |
110
-45
| -29% | -$497 | ﹤0.01% | 7189 |
|
|
2023
Q3 | $2.12K | Sell |
155
-899
| -85% | -$11.3K | ﹤0.01% | 7120 |
|
|
2023
Q2 | $12.8K | Sell |
1,054
-31,261
| -97% | -$356K | ﹤0.01% | 6721 |
|
|
2023
Q1 | $411K | Buy |
32,315
+27,334
| +549% | +$303K | ﹤0.01% | 5363 |
|
|
2022
Q4 | $31.5K | Buy |
4,981
+4,018
| +417% | +$71.1K | ﹤0.01% | 6491 |
|
|
2022
Q3 | $22K | Sell |
963
-900
| -48% | -$24.6K | ﹤0.01% | 6746 |
|
|
2022
Q2 | $35K | Buy |
1,863
+830
| +80% | +$20.5K | ﹤0.01% | 6769 |
|
|
2022
Q1 | $49K | Sell |
1,033
-698
| -40% | -$38.1K | ﹤0.01% | 6714 |
|
|
2021
Q4 | $123K | Buy |
1,731
+547
| +46% | +$55K | ﹤0.01% | 6315 |
|
|
2021
Q3 | $138K | Sell |
1,184
-2,526
| -68% | -$294K | ﹤0.01% | 6191 |
|
|
2021
Q2 | $581K | Buy |
3,710
+3,655
| +6,645% | +$671K | ﹤0.01% | 5432 |
|
|
2021
Q1 | $10K | Sell |
55
-22,870
| -100% | -$3.85M | ﹤0.01% | 6934 |
|
|
2020
Q4 | $2.88M | Buy |
22,925
+5,628
| +33% | +$638K | ﹤0.01% | 3830 |
|
|
2020
Q3 | $1.88M | Buy |
17,297
+3,891
| +29% | +$461K | ﹤0.01% | 3701 |
|
|
2020
Q2 | $1.61M | Buy |
13,406
+13,301
| +12,668% | +$1.87M | ﹤0.01% | 3792 |
|
|
2020
Q1 | $10K | Sell |
105
-1,519
| -94% | -$281K | ﹤0.01% | 6009 |
|
|
2019
Q4 | $394K | Buy |
1,624
+1,274
| +364% | +$238K | ﹤0.01% | 5067 |
|
|
2019
Q3 | $57K | Buy |
350
+334
| +2,088% | +$63.4K | ﹤0.01% | 5666 |
|
|
2019
Q2 | $4K | Sell |
16
-131
| -89% | -$32.4K | ﹤0.01% | 6349 |
|
|
2019
Q1 | $39K | Sell |
147
-228
| -61% | -$39.3K | ﹤0.01% | 5768 |
|
|
2018
Q4 | $34K | Sell |
375
-639
| -63% | -$87.1K | ﹤0.01% | 5865 |
|
|
2018
Q3 | $195K | Buy |
1,014
+983
| +3,171% | +$207K | ﹤0.01% | 5463 |
|
|
2018
Q2 | $7K | Buy |
+31
| New | +$7K | ﹤0.01% | 6368 |
|
Other funds holding DNTH
APM
RCM
FFM
VCM
OCA
TCM
Morgan Stanley's DNTH Position: Q1 2026 in Review
Morgan Stanley reduced its Dianthus Therapeutics (DNTH) stake by 57% in Q1 2026, selling an estimated $7.56M and leaving 97,455 shares worth $8.18M. The position accounts for ﹤0.01% of the portfolio, ranked #3741.
Morgan Stanley first reported a position in DNTH in Q2 2018 and has held it in 32 quarters since. The position peaked at $9.4M in Q4 2025. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.
- Morgan Stanley held 97,455 shares of Dianthus Therapeutics worth $8.18M as of Q1 2026.
- Morgan Stanley sold 130,561 Dianthus Therapeutics shares in Q1 2026, an estimated $7.56M.
- Dianthus Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #3741 holding.
- Morgan Stanley first reported a position in Dianthus Therapeutics in Q2 2018 and has held it in 32 quarters since.
- Morgan Stanley's Dianthus Therapeutics position peaked at $9.4M in Q4 2025.
- 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.